|
|
|
Danaher Corp | 5.00% Mandatory Convertible Preferred Stock, Series B Due 4/15/23 (DHR.PRB)
Prospectus excerpt: This pricing term sheet relates only to the securities described below and should be read together with (i) Danaher Corporation’s preliminary prospectus supplement dated May 7, 2020 relating to the Common Stock Offering (the “Common Stock Preliminary Prospectus Supplement”), the accompanying prospectus dated July 9, 2019 and the documents incorporated and deemed to be incorporated by reference therein (in the case of investors purchasing in the Common Stock Offering); and (ii) Danaher Corporation’s preliminary prospectus supplement dated May 7, 2020 relating to the Series B Mandatory Convertible Preferred Stock Offering (the “Series B Mandatory Convertible Preferred Stock Preliminary Prospectus Supplement” and, together with the Common Stock Preliminary Prospectus Supplement, the “Preliminary Prospectus Supplements”), the accompanying prospectus dated July 9, 2019 and the documents incorporated and deemed to be incorporated by reference therein (in the case of investors purchasing in the Series B Mandatory Convertible Preferred Stock Offering). Neither the Common Stock Offering nor the Series B Mandatory Convertible Preferred Stock Offering is contingent on the completion of the other offering. Danaher Corporation has increased the size of the Common Stock Offering to $1,550,000,089 (or $1,782,499,866 if the underwriters’ option to purchase additional shares of Common Stock is exercised) and the Series B Mandatory Convertible Preferred Stock Offering to $1,550,000,000 (or $1,717,500,000 if the underwriters’ option to purchase additional shares of Series B Mandatory Convertible Preferred Stock, solely to cover over-allotments, is exercised). The final preliminary prospectus supplement, dated May 7, 2020, relating to the Common Stock Offering and the final prospectus supplement, dated May 7, 2020, relating to the Series B Mandatory Convertible Preferred Stock Offering will reflect conforming changes relating to increases in the size of the offerings. Certain capitalized terms used in this pricing term sheet that are not defined herein but that are defined in the Common Stock Preliminary Prospectus Supplement or the Series B Mandatory Convertible Preferred Stock Preliminary Prospectus Supplement, as applicable, have the respective meanings given to such terms in such Preliminary Prospectus Supplement. Full Prospectus PDF », Secondary Prospectus PDF », DHR Page »
Series: | B | Alternate symbology: | DHR-B, DHR-PB, DHRprB | Redeemable?: | Yes | Maturity Date: | 4/15/2023 | Cumulative?: | Yes | Conversion Ratio: | 5.0081-6.1349 | Conversion Price: | $163-$199.68 | Shares Offered: | 1,550,000 | Liquidation Preference: | $1,000.00 | Original Coupon: | 5.00% | Pay Period: | Quarterly | Pay Dates: | 15-Jan, 15-Apr, 15-Jul, 15-Oct | CDx3 Compliance Rating: |
Learn DHR.PRB's Rating
|
|
Danaher designs, manufactures and markets medical, industrial and commercial products and services. Co.'s segments are: Biotechnology, which includes the bioprocessing and discovery and medical businesses and provides tools, consumables and services; Life Sciences, which provides instruments and consumables to understand the causes of disease, identify new therapies, and test and manufacture new drugs, vaccines and gene editing technologies; Diagnostics, which provides clinical instruments, reagents, consumables, software and services; and Environmental and Applied Solutions, which provides products and services that help protect resources and keep global food and water supplies safe. Preferreds: DHR.PRA, DHR.PRB Open the DHR Information Page »
|
Name: |
Danaher Corp |
Website: |
www.danaher.com |
Sector: |
Biotechnology |
Number of ETFs Holding DHR: |
97 (see which ones) |
Total Market Value Held by ETFs: |
$19,757,601,812.58 |
Total Market Capitalization: |
$185,475,000,000 |
% of Market Cap. Held by ETFs: |
10.65% |
|
|
|
|
|